Viking Therapeutics shares surged to a three-month high as retail traders speculated on potential M&A scenarios, including a $20 billion buyout or partnership with UnitedHealth. The chatter followed Pfizer acquisition of Metsera, reigniting interest in independent obesity drug developers. Some investors said Viking could reach a $50 billion valuation independently, calling it a 10x play.